Sean J Haley1, Andrew R Maroko2, Katarzyna Wyka3, Margaret Ryerson Baker4. 1. Department of Health Policy and Management, CUNY Graduate School of Public Health and Health Policy, New York, NY, United States of America. Electronic address: sean.haley@sph.cuny.edu. 2. Department of Environmental, Occupational, and Geospatial Health Sciences, CUNY Graduate School of Public Health and Health Policy, New York, NY, United States of America. 3. Department of Epidemiology and Biostatistics, CUNY Graduate School of Public Health and Health Policy, New York, NY, United States of America. 4. Institute of Implementation Science and Population Health, Department of Environmental, Occupational, and Geospatial Health Sciences, CUNY Graduate School of Public Health and Health Policy, New York, NY, United States of America.
Abstract
BACKGROUND: Increases in pharmaceutical opioid sales have paralleled the quadrupling of prescription opioid overdose deaths and spikes in emergency department visits for non-medical opioid prescription overdoses. In response, federal and state governments have advanced a myriad of policies to reduce opioid availability and increase treatment access, aimed to ultimately reduce opioid-related mortality. Despite these efforts, including ACA Medicaid expansion and more robust prescription drug monitoring programs, opioid-related mortality has continued to rise in NY and 29 other states. This study examined whether geographic access to Federally Qualified Health Centers, opioid treatment programs, and buprenorphine providers mitigated opioid-related hospital visits (emergency department, inpatient, and all visits) and mortality, by county, between 2012 and 2014. METHODS: The authors examined the relationships among opioid-related health outcomes and geographic access to treatment options using spatial error regression models at the county (n = 62) level in 2012 and 2014. Z-tests further assessed significant differences in access coefficients between 2012 and 2014. RESULTS: Of the 62 counties in New York State in 2014, 54 (87.1%) showed increased opioid overdose-related emergency department rates (t = 9.125, p < 0.001), and 37 (59.7%) showed mortality rate increases (t = 1.687, p < 0.1), compared to 2012. Regression models demonstrated significant negative relationships between county-level opioid-related mortality rates and geographic access to opioid treatment programs, Federally Qualified Health Centers in both 2012 and 2014 and buprenorphine providers concentration in 2014 while adjusting for county socio-demographics (all p values < 0.05). Access coefficients were not significantly different between 2012 and 2014 (p > 0.05). CONCLUSIONS: Greater geographic access to treatment services was protective against opioid-related mortality. Access to opioid treatment may not be sufficient to mitigate opioid-related hospital visits or mortality, but may offset climbing mortality rates in select counties.
BACKGROUND: Increases in pharmaceutical opioid sales have paralleled the quadrupling of prescription opioid overdose deaths and spikes in emergency department visits for non-medical opioid prescription overdoses. In response, federal and state governments have advanced a myriad of policies to reduce opioid availability and increase treatment access, aimed to ultimately reduce opioid-related mortality. Despite these efforts, including ACA Medicaid expansion and more robust prescription drug monitoring programs, opioid-related mortality has continued to rise in NY and 29 other states. This study examined whether geographic access to Federally Qualified Health Centers, opioid treatment programs, and buprenorphine providers mitigated opioid-related hospital visits (emergency department, inpatient, and all visits) and mortality, by county, between 2012 and 2014. METHODS: The authors examined the relationships among opioid-related health outcomes and geographic access to treatment options using spatial error regression models at the county (n = 62) level in 2012 and 2014. Z-tests further assessed significant differences in access coefficients between 2012 and 2014. RESULTS: Of the 62 counties in New York State in 2014, 54 (87.1%) showed increased opioid overdose-related emergency department rates (t = 9.125, p < 0.001), and 37 (59.7%) showed mortality rate increases (t = 1.687, p < 0.1), compared to 2012. Regression models demonstrated significant negative relationships between county-level opioid-related mortality rates and geographic access to opioid treatment programs, Federally Qualified Health Centers in both 2012 and 2014 and buprenorphine providers concentration in 2014 while adjusting for county socio-demographics (all p values < 0.05). Access coefficients were not significantly different between 2012 and 2014 (p > 0.05). CONCLUSIONS: Greater geographic access to treatment services was protective against opioid-related mortality. Access to opioid treatment may not be sufficient to mitigate opioid-related hospital visits or mortality, but may offset climbing mortality rates in select counties.
Authors: Parisa Bozorgi; Jan M Eberth; Jeannie P Eidson; Dwayne E Porter Journal: Int J Environ Res Public Health Date: 2021-04-16 Impact factor: 3.390